These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31974286)

  • 41. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
    Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary RBP and NGAL Levels are Associated with Nephropathy in Patients with Type 2 Diabetes.
    Wu J; Shao X; Lu K; Zhou J; Ren M; Xie X; Liu J; Xu Y; Ding Y; Shen X; Zhu C
    Cell Physiol Biochem; 2017; 42(2):594-602. PubMed ID: 28954270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.
    Garlo KG; White WB; Bakris GL; Zannad F; Wilson CA; Kupfer S; Vaduganathan M; Morrow DA; Cannon CP; Charytan DM
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):398-405. PubMed ID: 29339356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
    von Eynatten M; Baumann M; Heemann U; Zdunek D; Hess G; Nawroth PP; Bierhaus A; Humpert PM
    Eur J Clin Invest; 2010 Feb; 40(2):95-102. PubMed ID: 19912308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
    Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
    Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urinary beta-2 microglobulin increases whereas TIMP-2 and IGFBP7 decline after unilateral nephrectomy in healthy kidney donors.
    de Rooij ENM; Hoogeveen EK; Romijn FPHTM; van der Kooy SW; Veighey KV; Dekker FW; van Kooten C; Cobbaert CM; de Fijter JW
    Sci Rep; 2024 Jun; 14(1):12901. PubMed ID: 38839764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy.
    Hwang S; Park J; Kim J; Jang HR; Kwon GY; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    J Diabetes Complications; 2017 Dec; 31(12):1704-1709. PubMed ID: 29037450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between urinary kidney injury biomarkers and cardiovascular mortality risk in elderly men with diabetes.
    Tonkonogi A; Carlsson AC; Helmersson-Karlqvist J; Larsson A; Ärnlöv J
    Ups J Med Sci; 2016 Aug; 121(3):174-8. PubMed ID: 27321055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-TGF-
    Voelker J; Berg PH; Sheetz M; Duffin K; Shen T; Moser B; Greene T; Blumenthal SS; Rychlik I; Yagil Y; Zaoui P; Lewis JB
    J Am Soc Nephrol; 2017 Mar; 28(3):953-962. PubMed ID: 27647855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus.
    Li A; Yi B; Liu Y; Wang J; Dai Q; Huang Y; Li YC; Zhang H
    J Immunol Res; 2019; 2019():5063089. PubMed ID: 31637265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.
    Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.